Axelios 1
搜索文档
Illumina, Inc.: Upgrading to Overweight on a Sticky Clinical User Base and Test Volume Runway Following Customer Survey; PT to $185-20260610
JPMorgan· 2026-06-10 18:10
J P M O R G A N North America Equity Research 10 June 2026 Illumina, Inc. Upgrading to Overweight on a Sticky Clinical User Base and Test Volume Runway Following Customer Survey; PT to $185 Marta Nazarovets Zaremba (1-212) 622-6046 marta.zaremba@jpmchase.com Jaden Rismay (1-212) 622-8479 jaden.rismay@jpmchase.com Sebastian Sandler (1-212) 622-8464 sebastian.sandler@jpmchase.com J.P. Morgan Securities LLC Illumina (ILMN) has been one of the most highly debated stocks in our space over the last year and a hal ...
Life Science Tools & Diagnostics Academic and Clinical ILMN Customer Survey: Insights into Market Views of Axelos1-20260610
JPMorgan· 2026-06-10 17:09
North America Equity Research June 2026 Life Science Tools & Diagnostics PM summary: Illumina (ILMN) Customer Survey Academic and Clinical ILMN Customer Survey: Insights into Market Views of Axelios 1 Life Science Tools & Diagnostics Casey Woodring AC +1 212 622 9074 casey.woodring@jpmchase.com J.P. Morgan Securities LLC Jaden Rismay +1 212 622 8479 jaden.rismay@jpmchase.com J.P. Morgan Securities LLC Sebastian Sandler +1 646 538 9821 sebastian.sandler@jpmchase.com J.P. Morgan Securities LLC Marta Nazarovet ...